Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's strategic plan highlights strong clinical progress, particularly with pemvidutide's development in MASH and AUD, and positive market research in Europe. The Q&A session revealed no major negative concerns, and the company has a solid financial runway. The FDA's cautious stance on NITs as endpoints is a minor setback but does not overshadow the overall positive sentiment. The absence of market cap data limits the prediction's precision, but the strategic advancements suggest a positive stock price movement.
Key Financial Performance
R&D expense (Q4 2025) $18.4 million, a decrease from $19.8 million in Q4 2024. The decrease is related to the end of the Phase IIb trial in late 2025.
Direct costs related to pemvidutide development (Q4 2025) $12.8 million, including $3.1 million for the IMPACT Phase IIb trial, $7.4 million for Phase II trials in AUD and ALD, and $1.2 million in CMC-related expenses.
G&A expenses (Q4 2025) $10.5 million, an increase from $5.1 million in Q4 2024. The increase was driven by a one-time noncash and cash stock compensation and payroll charge due to executive transition ($2.6 million), along with increases in professional fees and other compensation-related expenses.
Net loss (Q4 2025) $27.4 million or $0.27 per share, compared to $23.2 million or $0.33 per share in Q4 2024. The increase in net loss is attributed to higher G&A expenses.
Total full-year 2025 cash OpEx Approximately $67.5 million, excluding noncash compensation of $16 million.
Total cash (Year-end 2025) $274 million, bolstered by net proceeds of approximately $208 million from equity capital raised ($174 million) and funding from the Hercules tranche loan facility ($35 million).
Pro forma cash position (January 2026) Approximately $340 million, including $75 million raised in a registered direct offering and $8 million from the ATM facility in January.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pemvidutide: Focused on liver diseases, particularly MASH. Demonstrated strong therapeutic potential in Phase IIb trials with significant MASH resolution at 24 weeks and antifibrotic activity at 48 weeks. FDA Breakthrough Therapy designation received. Phase III trial planned with simplified dosing and titration.
Market Research Insights: Conducted research with 75 U.S. healthcare professionals. Identified unmet needs in MASH treatment, including alternatives for patients discontinuing semaglutide and therapies addressing muscle mass loss. Physicians showed high interest in pemvidutide, with over 70% likely to prescribe it.
Financial Position: Raised $75 million in January 2026, with a total cash position of $340 million. Current cash runway extends into 2028, supporting Phase III trials and other programs.
Team Expansion: Enhanced team with experts in liver disease, late-stage clinical development, and commercial strategy to support pemvidutide's advancement.
Strategic Focus: Exclusively targeting liver diseases with pemvidutide. Positioned as a combination therapy in a single molecule, addressing both hepatic and metabolic drivers of MASH. Differentiated from multidrug approaches.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company is preparing for a Phase III trial and has aligned with the FDA on trial design. However, there are still pending requests for scientific advice from the European Medicines Agency and the MHRA, which could pose challenges if feedback differs from expectations.
Financial sustainability: The company raised $75 million in January and has a cash position of $340 million, which is expected to provide an operating runway into 2028. However, the initiation of the Phase III trial and other ongoing trials will increase cash burn, necessitating strategic and opportunistic capital raising.
Market competition: The MASH treatment market is evolving, with multiple companies pursuing combination strategies. Pemvidutide must demonstrate clear differentiation and efficacy to compete effectively against existing and emerging therapies.
Patient adherence and tolerability: The tolerability of pemvidutide is a key focus, as adverse events and complex titration schemes in other therapies have led to patient drop-offs. The company plans to address this with a simplified titration scheme, but this remains a potential risk.
Operational execution: The company is finalizing the protocol and operational plan for a large-scale global Phase III trial involving approximately 1,800 patients. Any delays or inefficiencies in execution could impact timelines and costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III trial initiation for pemvidutide in MASH: The company plans to initiate a Phase III trial for pemvidutide in MASH this year. The trial will enroll approximately 1,800 patients globally, with a primary focus on patients with moderate to advanced fibrosis. The trial design includes a 52-week endpoint to support potential accelerated approval and a 5-year clinical outcomes data for final approval.
Phase II trial updates for AUD and ALD: The Phase II AUD trial completed enrollment in late 2025, with top-line data expected in Q3 2026. The Phase II ALD trial is expected to complete enrollment in 2026.
Projected product profile for pemvidutide: The company anticipates pemvidutide to demonstrate quality weight loss (8%-10%) with lean muscle preservation, favorable tolerability, and efficacy in addressing both hepatic and metabolic drivers of MASH. This profile is expected to differentiate pemvidutide from other therapies.
Regulatory alignment and global trial design: The company has aligned with the FDA on the Phase III trial design and has submitted requests for scientific advice to the European Medicines Agency and MHRA. The trial will include sites in North and South America, Europe, and Asia.
Financial position and funding: The company has a cash position of approximately $340 million, providing an operating cash runway into 2028. This funding is expected to support the Phase III trial for MASH and ongoing Phase II trials for AUD and ALD.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you talked with the FDA about the new single pivotal framework for Phase III, and is it possible to save costs if FDA allows amendments?
A:The company has not discussed this at the end of the Phase II meeting. The path for approval for the MASH programs involves one single trial for accelerated approval and final approval for clinical outcomes. This framework does not apply to their program, so there are no changes to their development approach.
Q:Can you share any strategic plans regarding the interim versus final outcome of alpha split and the two primary endpoints for the interim?
A:The Phase III design includes two primary endpoints as per FDA guidance: MASH resolution without worsening of fibrosis and fibrosis improvement without MASH worsening. The study is powered at more than 90% with a sample size of around 990 patients (330 per arm). The alpha split is 0.1 for accelerated approval and the rest for clinical outcomes. The study is powered based on the 1.8 mg dose, with an option for a 2.4 mg dose for potential added benefits.
Q:Where does the FDA stand on flexibility to consider NITs as a potentially registrational endpoint, and what are the plans for MASH F4?
A:The FDA considers it premature to use NITs as registrational endpoints, so the study will use biopsy-driven endpoints while capturing NIT data. For MASH F4, the focus is currently on F2/F3, with potential for F4 impact due to the mechanism of action, but the team is dedicated to executing Phase III for now.
Q:What are the limiting steps to kick off the Phase III study, and what are the timelines for enrollment and top-line data?
A:The company is preparing on financial and operational fronts, with alignment from the FDA and European regulators. The trial is expected to start this year, with guidance narrowing as preparations progress. Execution and finalizing protocol details are the current focus.
Q:What are your thoughts on the RECLAIM trial and what would be considered clinically meaningful on alcohol usage?
A:The RECLAIM trial analyzes heavy drinking days over a week and is powered to detect a conservative change. Other endpoints include zero drinking days and WHO risk classifications. The mechanism of action targets both the reward system and direct liver effects, which is unique compared to other developments.
Q:What are your plans for additional financing to complete Phase III in the MASH program?
A:The company has $340 million on the balance sheet as of February, providing runway into 2028. They are exploring options to strengthen resources as they prepare to launch the trial this year.
Q:What are the key data points from competitors in obesity that may translate into MASH and impact the competitive landscape?
A:The company focuses on tolerability, quality weight loss, and simplicity of titration as key differentiators. They are monitoring competitors like retatrutide and survodutide but believe their balanced ratio and tolerability profile provide a competitive edge. The focus remains on MASH patients (F2/F3).
Q:Did the FDA provide clarity on using NITs as primary endpoints or AI biopsy reads for accelerated approval?
A:The FDA considers NITs premature but the company is prepared if this changes. AI biopsy reads aim to reduce variability and placebo response, streamlining the process. Discussions with key pathologists and PathAI are ongoing.
Q:What is the company's CMC manufacturing readiness for global trial supply?
A:The company is ready for Phase III manufacturing and focused on MASH trials. They can scale for obesity if needed but are prioritizing MASH indications globally.
Q:What are the key elements locked in for the Phase III trial, and what is the biggest remaining variable?
A:Key elements like sample size, primary endpoints, and population are finalized. The main remaining variable is finalizing biopsy processes with pathologists to ensure comprehensive execution.
Q:What is the mechanism of action for pemvidutide in AUD and ALD, and how will the Phase III program proceed?
A:The mechanism targets the reward system (GLP-1) and direct liver effects (glucagon). The company will assess AUD trial data in Q3 before planning next steps, without waiting for ALD data.
Q:What are the inclusion/exclusion criteria for semaglutide failures in the Phase III trial, and how is the pathologist panel structured?
A:Semaglutide failures will be included if they meet criteria, offering an option with pemvidutide's efficacy and tolerability. The pathologist panel will likely use a 2+1 consensus model, with AIM-MASH Assist reducing variability and streamlining processes.
Q:Are there any NITs in the RECLAIM trial, and what is the status of ALD trial enrollment?
A:The RECLAIM trial includes liver enzymes, PEth, and WHO risk classifications but focuses on alcohol consumption metrics. ALD enrollment is on track but slower due to the severe population.
Q:Will the Phase III trial evaluate cardiovascular benefits or MACE?
A:The trial will include data on lipids and inflammation but will not use cardiovascular outcomes as primary endpoints, per FDA guidance.
Q:How does pemvidutide preserve muscle, and what tests are used to monitor this?
A:Muscle preservation is consistent across BMI ranges and may be linked to the 1:1 ratio. Tests like MRI and DEXA are being considered, with plans for a sub-study or mechanistic study in Phase III.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for enrollment and top-line data in the Phase III trial, stating only that guidance would narrow as preparations progress. They also did not provide detailed updates on ALD trial enrollment or specific financial strategies for additional funding, using vague language about 'options' and 'line of sight.'
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Altimmune
Christophe
GI
II trial
III trial
MASH Phase
MASH patient
Phase II
Phase III
addition
adherence
concern
design
disease
effect
efficacy
endpoint
health care
liver
mass
milligram dose
muscle
noncash
pemvi patient
pemvidutide
physician
quality weight
result
safety
step titration
study
therapy
tolerability profile
treatment
weight loss
ALT Transcript
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Positive3-5
The company's strategic plan highlights strong clinical progress, particularly with pemvidutide's development in MASH and AUD, and positive market research in Europe. The Q&A session revealed no major negative concerns, and the company has a solid financial runway. The FDA's cautious stance on NITs as endpoints is a minor setback but does not overshadow the overall positive sentiment. The absence of market cap data limits the prediction's precision, but the strategic advancements suggest a positive stock price movement.
Conagra Brands, Inc. (CAG) Q2 2026 Earnings Call Transcript
Unknown12-19
The earnings call summary presents a mixed outlook. Financial performance and shareholder return plans are not explicitly detailed, leading to a neutral stance. Product development, particularly the advancement of Pemvidutide, is promising but lacks immediate impact. Market strategy seems stable, with no new partnerships or significant changes. The Q&A reveals management's cautious stance on guidance and inflation, suggesting uncertainties. With no new partnerships or guidance changes, the stock is likely to remain stable, resulting in a neutral prediction for the stock price over the next two weeks.
Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-20
Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary reveals strong financial health with increased cash reserves and reduced net loss. Product development is progressing, with promising trials and strategic FDA interactions. The Q&A highlights optimism about innovative approaches, like AI-based biopsy readings, and differentiation in competitive markets. Despite some unclear responses, the overall sentiment is positive due to financial stability, strategic developments, and potential market differentiation.
ALT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
